NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

3 Months Ended

Dec. 31, 2020

7. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of December 31,		As of September 30,
	2020		2020
Accrued compensation and benefits	$	57,274	$	88,527
Accrued professional fees		407,235		241,755
Accrued research and development		40,656		41,313
Accrued franchise tax		194,831		155,865
Other accrued expenses		43,852		28,423
Total	$	743,848	$	555,883